ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
WESTON, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; 'ZyVersa'), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that the Clinical Advancement Center, PLLC in San Antonio, Texas is the first clinical site activated and ready for patient recruitment in our VAR 200 Phase 2a clinical study in patients with DKD. The lead investigator is Pablo Pergola, MD, PhD.
'We are pleased to work with Dr. Pergola and his research colleagues at the Clinical Advancement Center to kick off our first-in-human VAR 200 Phase 2a trial in patients with DKD. We share a similar vision to that of Dr. Pergola and the Clinical Advancement Center – to develop innovative treatments that will change the course of kidney disease and improve patients' quality of life,' said Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President. 'It is this vision that led us to develop a drug, VAR 200, that targets a neglected pathogenic pathway in kidney disease – excess accumulation of cholesterol and lipids in the glomerulus, the main filtering unit of the kidney. There is a large body of evidence demonstrating the critical need for therapies to address kidney lipotoxicity, a key pathway in development and progression of DKD and other kidney diseases. Despite newer treatment options for kidney disease, over 130,000 patients progress to renal failure each year in the US, and more than 800,000 patients are living with renal failure requiring dialysis or transplant to sustain life. We believe that adding VAR 200 to standard-of-care drugs, like ACEs, ARBs, and SGLT2 inhibitors that address other pathogenic pathways, will be disease-modifying and better protect against further kidney injury and disease progression. We look forward to seeing the results of this Phase 2a trial, and to progressing VAR 200 to commercialization.'
VAR 200's proof-of-concept Phase 2a study will be conducted at one to two US sites and will enroll an adequate number of subjects to complete eight. It is a 16-week open-label study (12 weeks of treatment and a four-week follow-up period) to evaluate the drug's efficacy and safety in patients with type 2 diabetes and diabetic kidney disease with proteinuria. VAR 200 will be administered intravenously twice weekly at a single dose and will be added to the stable drug regimen used by each patient. The primary efficacy endpoint is percent change from baseline to week 12 in urinary albumin to creatinine ratio. Further details can be found at clinicaltrials.gov.
ABOUT CHOLESTEROL EFFLUX MEDIATOR™ VAR 200
Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is an injectable drug in phase 2 development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to development and progression of kidney disease. VAR 200 removes excess lipids from the kidney both passively, and actively by upregulation of cholesterol efflux transporters, ABCA1 and ABCG.
Preclinical studies with VAR 200 in animal models of FSGS, Alport syndrome, and diabetic kidney disease demonstrate reduced levels of cholesterol and lipids, protection against renal injury and fibrosis, and improvement in proteinuria. Additional information can be found in the VAR 200 White Paper.
The lead indication for VAR 200 is orphan kidney disease, focal segmental glomerulosclerosis (FSGS). Prior to initiating a Phase 2a trial in patients with FSGS, we are conducting a small Phase 2a trial in patients with diabetic kidney disease, which we expect will provide patient proof-of-concept more quickly than an FSGS study. Alport Syndrome and diabetic kidney disease indications may be pursued based on our indication expansion strategy.
ABOUT ZYVERSA THERAPEUTICS, INC.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit www.zyversa.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management's intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. ('ZyVersa') uses words such as 'anticipates,' 'believes,' 'plans,' 'expects,' 'projects,' 'future,' 'intends,' 'may,' 'will,' 'should,' 'could,' 'estimates,' 'predicts,' 'potential,' 'continue,' 'guidance,' and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa's plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa's planned preclinical and clinical trials; the timing of the availability of data from ZyVersa's preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa's product candidates; ZyVersa's commercialization, marketing and manufacturing capabilities and strategy; ZyVersa's ability to protect its intellectual property position; and ZyVersa's estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.
Corporate, IR, and Media Contact
Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
E&E News
10 minutes ago
- E&E News
Grid battery installations may plunge 29% due to Congress, Trump — report
The utility-scale energy storage market is at risk of plunging 29 percent next year because of 'policy uncertainty' from tariffs and potential rollbacks of key tax credits in Congress, according to a new report. The analysis from Wood Mackenzie and the American Clean Power Association found that energy storage — which is dominated by lithium-ion batteries — experienced record growth in the first quarter of 2025, adding 2 gigawatts. Utility-scale battery installations alone increased 57 percent in comparison to the same quarter last year. But federal policy could cause a sharp reversal in 2026, with implications for renewables tied to batteries and grid stability in regions with surging power demand. Among the threats is the end of some Biden-era clean energy tax credits, as outlined in the House and Senate versions of President Donald Trump's 'big, beautiful bill.' Advertisement The industry's quarterly results 'demonstrate the demand for energy storage in the US to serve a grid with both growing renewables and growing load. However, the industry stands at a crossroads, with potential policy changes threatening to disrupt this momentum,' Allison Weis, global head of energy storage at Wood Mackenzie, said in a statement.
CNET
12 minutes ago
- CNET
Free Money from 23andMe's Data Breach Settlement: Here's How to File Your Claim
Hackers used a credential stuffing attack to gain access to 23andMe accounts in October 2023. Getty Images/Viva Tung/CNET Ever used 23andMe? Well, now you may be able to get paid as part of the company's ongoing class-action settlement, but you'll have to move quickly. It's been a tough few years for the once-popular ancestry-tracking service, which in 2023 was struck by a prolonged data breach that allowed hackers to gain personal data for about half of the company's 14 million customers. The company has struggled ever since then and filed for bankruptcy in March 2025. It is now being acquired by TTAM Research Institute, a nonprofit led by 23andMe co-founder Anne Wojcicki, which outbid Regeneron Pharmaceuticals. The San Francisco-based company, which allows people to submit genetic materials and get a snapshot of their ancestry, announced in October 2023 that hackers had accessed customer information in a data breach. A January 2024 lawsuit accused the company of not doing enough to protect its customers and not notifying certain customers with Chinese or Ashkenazi Jewish ancestry that their data had been targeted specifically. It later settled the lawsuit for $30 million. "We have executed a settlement agreement for an aggregate cash payment of $30 million to settle all US claims regarding the 2023 credential stuffing security incident," a 23andMe spokesman told CNET. "We continue to believe this settlement is in the best interest of 23andMe customers, and we look forward to finalizing the agreement." A few months after that decision, there's now an official method available to make a claim and potentially get paid by 23andMe, in some cases as much as $10,000. Keep reading to get all the details you need, and for more, find out why T-Mobile settlement checks have been delayed and discover whether you can claim a piece of Apple's Siri privacy settlement. How many people did the 23andMe data breach hit? The settlement could cover roughly 6.9 million 23andMe customers whose data was targeted. To qualify, 23andMe customers must also have been US residents as of Aug. 11, 2023. That 6.9 million number includes around 5.5 million customers of 23andMe's DNA Relatives profiles, which lets people find and connect with genetic relatives. The other 1.4 million people affected by the breach used another service known as Family Tree, which predicts a family tree based on the DNA users share with relatives, 23andMe said. How much money could I get from the settlement? At the top end, 23andMe has said it would pay out up to $10,000 with an "Extraordinary Claim" to each customer who can verify that they suffered hardships as a direct result of their information being stolen in the data breach that resulted in unreimbursed costs. This includes costs from "identity fraud or falsified tax returns," acquiring physical security systems, or receiving mental health treatment. Residents of Alaska, California, Illinois and Oregon who were affected by the data breach can also apply for a payment as part of the proposed settlement, since those states have genetic privacy laws with damages provisions. The payments for these individuals are expected to be around $100, depending on how many people file for them, a settlement document said. Also, a smaller subset of affected users whose personal health information was impacted by the breach will be able to apply for a payment of $100. Infographic: Gianmarco Chumbe/CNET. Photo:Will the 23andMe settlement include anything else? Beyond those payments, 23andMe will also offer impacted users three years of a security monitoring service called Privacy Shield, which filings described as providing "substantial web and dark web monitoring." How can I file a claim for the 23andMe settlement? To file a claim electronically, you can use this official online portal from the Kroll Restructuring Administration. An additional online form is available if you would like proof of your claim sent to you. Potential claimants can also download and print out hard copies of the claim form and proof of claim form if they wish to submit them by mail. If you plan to use this method, send your forms to one of the addresses listed on the claims website. The deadline to make a claim is July 14. For more, you can read about how class action lawsuits work.
CNN
13 minutes ago
- CNN
Migrant family sues over US detention in what may be first challenge to courthouse arrests involving kids
ImmigrationFacebookTweetLink Follow A mother and her two young kids are fighting for their release from a Texas immigration detention center in what is believed to be the first lawsuit involving children challenging the Trump administration's policy on immigrant arrests at courthouses. The lawsuit filed Tuesday argues that the family's arrests after fleeing Honduras and entering the US legally using a Biden-era appointment app violate their Fourth Amendment right to be free from unreasonable searches and seizure and their Fifth Amendment right to due process. 'The big picture is that the executive branch cannot seize people, arrest people, detain people indefinitely when they are complying with exactly what our government has required of them,' said Columbia Law School professor Elora Mukherjee, one of the lawyers representing the family. The Department of Homeland Security did not immediately respond to an email requesting comment. Starting in May, the country has seen large-scale arrests in which asylum-seekers appearing at routine court hearings have been arrested outside courtrooms as part of the White House's mass deportation effort. In many cases, a judge will grant a government lawyer's request to dismiss deportation proceedings and then US Immigration and Customs Enforcement officers will arrest the person and place them on 'expedited removal,' a fast track to deportation. Mukherjee said this is the first lawsuit filed on behalf of children to challenge the ICE courthouse arrest policy. The government has until July 1 to respond. There have been other similar lawsuits, including in New York, where a federal judge ruled earlier this month that federal immigration authorities can't make civil arrests at the state's courthouses or arrest anyone going there for a proceeding. The Texas lawsuit was filed using initials for the children and 'Ms. Z' for the mother. Their identities have not been released because of concerns for their safety. For weeks in the Dilley Immigration Processing Center, the mother has watched her 6-year-old son's health decline, Mukherjee said. He recently underwent chemotherapy treatment for leukemia and because of his arrest missed his check-in doctor's appointment, Mukherjee said. 'He's easily bruising. He has bone pain. He looks pale,' Mukherjee said, adding that he has also lost his appetite. 'His mom is terrified that these are symptoms that his leukemia situation might be deteriorating.' The mother, son and 9-year-old daughter fled Honduras in October 2024 due to death threats, according to the lawsuit. They entered the US using the CBP One app and were paroled into the country by the Department of Homeland Security, which determined they didn't pose a danger to the community, Mukherjee said. They were told to appear at a Los Angeles immigration court May 29. President Donald Trump ended CBP One for new entrants on his first day in office after more than 900,000 people had been allowed in the country using the app since it was expanded to include migrants in January 2023. During the family's hearing, the mother tried to tell the judge that they wished to continue their cases for asylum, Mukherjee said. Homeland Security moved to dismiss their cases, and the judge immediately granted that motion. When they stepped out of the courtroom, they found men in civilian clothing believed to be ICE agents who arrested the family, Mukherjee said. They spent about 11 hours at an immigrant processing center in Los Angeles and were each only given an apple, a small packet of cookies, a juice box and water. At one point, an officer near the boy lifted his shirt, revealing his gun. The boy urinated on himself and was left in wet clothing until the next morning, Mukherjee said. They were later taken to the processing center, where they have been held ever since. 'The family is suffering in this immigration detention center,' she said. 'The kids are crying every night. They're praying to God for their release from this detention center.' Their lawyers have filed an appeal of the immigration judge's May decision, but they're at risk of being deported within days because the government says they are subjected to expedited removal, Mukherjee said. The arrests of the family were illegal and unjustified, said Kate Gibson Kumar, an attorney for the Texas Civil Rights project who is also representing the family. 'The essential question in our case is, when you have these families who are doing everything right, especially with young children, should there be some protection there?' Gibson Kumar said. 'We say 'yes.''
